Back to Search
Start Over
MiR-302a-3p reduces cisplatin resistance of esophageal squamous cell carcinoma cells by targeting EphA2
- Source :
- Journal of Chemotherapy; January 2024, Vol. 36 Issue: 1 p72-81, 10p
- Publication Year :
- 2024
-
Abstract
- AbstractPlatinum-based chemotherapy is a common clinical treatment for esophageal squamous cell carcinoma (ESCC), and chemoresistance is a major leading reason for cancer treatment failure. MiR-302a-3p is involved in the development of many diseases. Here, we investigated the role of miR-302a-3p in the cisplatin resistance of ESCC cells and explored its potential mechanism viamolecular techniques. The expression of miR-302a-3p was significantly reduced, while the expressions of EphA2 were increased in ESCC tumor tissues and cells. EphA2 was one target gene of miR-302a-3p, and was negatively regulated by miR-302a-3p. By regulating EphA2, miR-302a-3p reduced the viability and promoted the apoptosis of ECA109 cells treated with cisplatin, suggesting that miR-302a-3p could enhance the sensitivity of ECA109 cells to cisplatin treatment by targeting EphA2. MiR-302a-3p plays an important role in reducing cisplatin resistance by inhibiting EphA2, suggesting that it may be a promising therapeutic strategy for cisplatin resistance in ESCC in the future.
Details
- Language :
- English
- ISSN :
- 1120009X and 19739478
- Volume :
- 36
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Journal of Chemotherapy
- Publication Type :
- Periodical
- Accession number :
- ejs65275179
- Full Text :
- https://doi.org/10.1080/1120009X.2023.2213490